Q2 2024 Nanoform Finland Oyj Earnings Call Transcript
Key Points
- Nanoform Finland PLC (STU:4YL) has achieved significant progress in 2024, including preparing to put medicines on the market and signing several new customer projects.
- The company has been awarded the GMP Quality Control lab certificate, enabling faster analysis and a lower cost position for customers.
- Nanoform Finland PLC (STU:4YL) is on track to meet its 2024 business targets, including increased project signings and improved operating free cash flow.
- The company has a strong balance sheet with more than EUR 50 million in cash and short-term government bonds, and no debt.
- Nanoform Finland PLC (STU:4YL) has seen increased traction in biologics, particularly after a presentation by Takeda, and has signed a multi-API contract with a major US pharma company.
- The growth rate in personnel has slowed down as the company feels it has reached critical mass, potentially indicating a plateau in expansion.
- Revenue per quarter has seen only a small sequential increase, with the 12-month rolling revenue still down slightly.
- The company has experienced fluctuations in project signings, with some quarters seeing only one or two signings.
- There is a dependency on external partners for certain aspects of R&D, which could impact timelines and costs.
- The company is still in the process of finalizing the formulation work for nanoenzalutamide, which could delay market entry.
Good afternoon, all, and a warm welcome to Nanoform's second-quarter 2024 report presentation. My name is Henri von Haartman, and I'm your Director of Investor Relations. Today, our CEO, Edward Haeggstrom; CFO, Albert Haeggstrom; and Chief Commercial Officer, Christian Jones, will present to you.
This presentation is webcasted through Financial Hearings and there is also the possibility to call in and listen by phone. The presentation slides are shown throughout the webcast and they can also be found on our webpage in the investor section.
After the presentation, we will hold a Q&A, and it's possible to ask questions by calling in. We will, today, start with introduction to Nanoform, then financials and then we conclude with commercial.
With these words, our CEO, Founder, Professor Edward Haeggstrom, please go ahead.
Thank you, Henri. And welcome, also, on my
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
